It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common ...

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 7.4% in the morning session after the ...

Historical evidence indicates that abrupt market fluctuations can affect any corporation, regardless of its perceived dominance.

We recently published 10 Stocks With Monster Gains. Eli Lilly and Company (NYSE:LLY) was one of the top performers on ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Eli Lilly stock jumps 8% after Q4 earnings beat. Revenue hits $19.3B driven by Mounjaro and Zepbound sales growth.

Eli Lilly and Co (NYSE: LLY) has outperformed the market over the past 5 years by 26.12% on an annualized basis producing an average annual return of 38.25%. Currently, Eli Lilly and Co has a market ...

Eli Lilly LLY and Novo Nordisk NVO, long-standing rivals and the two dominant forces in the GLP-1 obesity market, are now locked in an intensified battle as both companies slash prices to defend and ...

In this photo illustration, a Eli Lilly logo seen displayed on a smartphone. Eli Lilly’s stock (NYSE: LLY) has recently surged 27% over the past month, reaching a current price of $1,022. This rally ...

Eli Lilly’s Q4 beat and bullish 2026 guidance highlight GLP-1 strength from Mounjaro/Zepbound, supporting a $1240–1300 target ...

Eli Lilly LLY has pursued a series of acquisitions since early 2025 to strengthen its pipeline and support long-term growth amid intensifying competition in the obesity space. While cardiometabolic ...